DCF Valuation: The Stock Market Sanity Check For most

New Post Public Reply Private Reply Replies (0) Message Board

Dec 2, 2012 at 8:03 AM

DCF Valuation: The Stock Market Sanity Check For most people, discounted cash flow (DCF) valuation seems like a form of financial black art, best left to Ph.D.s and Wall Street technical wizards. DCF intricacies do involve complex math and financial modeling, but if you understand the basic concepts behind DCF, you can perform "back-of-the-envelope" calculations to help you make investment decisions or value small businesses. This article, will discuss a few practical applications. DCF Usages Let's begin with a brief overview. DCF is a valuation method that can be used for privately-held companies. It projects a series of future cash flows, EBITDA or earnings and then discounts for the time value of money, typically using the company's own weighted average cost of capital (WACC) over a period of five to 10 years. The sum of all future discounted flows is the company's present value. Professional business appraisers often include a terminal value at the end of the projected earnings period, and they also may apply discounts for small-company risk, lack of liquidity or shares representing a minority interest in the company. An Acid Test for Valuing a Public Stock DCF is a blue-ribbon standard for valuing privately-held companies; it can also be used as an acid test for publicly-traded stocks . Public companies in the United States may have P/E ratios (determined by the market) that are higher than DCF. This is especially true of smaller, younger companies with high costs of capital, and uneven or uncertain earnings or cash flow. But it also can be true of large, successful companies with astronomical P/E ratios. For example, let's do a simple DCF test to check whether Apple stock was fairly valued at a given point in time. During June of 2008, Apple had a market capitalization of $150 billion. The company was generating operating cash flow of around $7 billion per year and we'll assign a WACC of 7% to the company, because it is financially strong and can raise equity and debt capital inexpensively. We'll also assume that Apple can increase its operating cash flow by 15% per year over the 10-year period, a somewhat aggressive assumption because few companies are capable of sustaining such high growth rates over lengthy periods. On this basis, DCF would value Apple at a market capitalization of $106.3 billion, 30% below its stock market price at the time. In this case, DCF provides one indication that the market may be paying too high of a price for Apple common stock. Smart investors might look to other indicators, such as inability to sustain cash flow growth rates in the future, for confirmation. The Importance of WACC on Stock Market Valuations Doing just a few DCF calculations demonstrates the link between a company's cost of capital and its valuation. For large public companies (such as Apple), the cost of capital tends to be somewhat stable. But for small companies, this cost can fluctuate significantly over economic and interest rate cycles. The higher a company's cost of capital, the lower its DCF valuation will be. For the smallest companies (below about $500 million in market cap), DCF technicians may add a "size premium" of 2-4% to the company's WACC to account for extra risk. During the credit crunch of 2007 and 2008, the cost of capital for the smallest public companies soared as banks tightened lending standards. Some small public companies that could tap bank credit at 8% in 2006 suddenly had to pay 12-15% to hedge funds for increasingly-scarce capital. Using simple DCF valuation, let's see what the impact of increasing WACC from 8% to 14% would be on a small public company with $10 million in annual cash flow and projected annual cash flow growth of 12% over a 10-year period. Net present value of the company @ 8% WACC $143.6 million Net present value of the company @ 14% WACC $105.0 million Decline in net present value $ $38.6 million Decline in net present value % 26.9% Based on the higher cost of capital, the company is valued at $38.6 million less, representing a 26.9% decline in value. Building a Company's Value If you are building a small company and hope to sell it one day, DCF valuation can help you focus on what is most important - generating steady growth on the bottom line. In many small companies, it's difficult to project cash flow or earnings years into the future, and this is especially true of companies with fluctuating earnings or exposure to economic cycles. A business valuation expert is more willing to project growing cash flows or earnings over a lengthy period when the company has already demonstrated this ability. Another lesson taught by DCF analysis is to keep your balance sheet as clean as possible by avoiding excessive loans or other forms of leverage. Awarding stock options or deferred compensation plans to a company's top executives can strengthen a company's appeal to attract quality management, but it can also create future liabilities that will increase the company's cost of capital. The Bottom Line DCF valuation isn't just financial rocket science. It also has practical applications that can make you a better stock market investor because it serves as an acid test of what a public company would be worth if it were valued the same as comparable private companies. Astute, value-minded investors use DCF as one indicator of value, and also as a "safety check" to avoid paying too much for shares of stock, or even a whole company.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Testing Grounds: Navigating PRN Test Insights

Deciphering the PRN Tester Repetition Today we're staring at what feels like déjà vu—a simple PR test peppered with the classic sentence about a fox and a dog. It's like someone left the 'repeat' function stuck on during a slow day at the office. But hey, let’s dig in. Is there something more behind this repetitive text, or are we grumbling at a wall? Unpacking the...

TECNO's Modular Phone and Mini-PC Win Big at IFA 2026

The Tale of Two Game-Changers TECNO has just scooped up two big-time awards, and I'm here to break it down like no glossy magazine ever could. Picture this: a brand that knows how to keep its foot on the innovation pedal and doesn't shy away from shaking up the tech world. TECNO's got the goods, claiming two prestigious IFA Global Product Technology Innovation Awards this...

HKC and KOORUI Shine Bright at 2026 Berlin Awards

Display Titans Take Center Stage in Berlin Look, in this game of display tech, you either adapt or get left in the dust. At the 2026 Global Product Technology Innovation Awards in Berlin, we saw two names rise to the top—HKC and its acclaimed brand KOORUI. They didn't just show up; they grabbed the spotlight with two major honors. Award Spotlights: A Breakdown HKC took...

Signant and Lothar Forge Future in Clinical Trials

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Affleck Joins Aflac in Unlikely Yet Fitting Alliance

A Partnership Born from a Punning Connection Look, in this world of insurance and Hollywood glitz, it's not every day you see Ben Affleck sharing the screen with a talking duck. But here we are. Aflac—the giant in supplemental health insurance—and Ben Affleck have cozied up for a series of ads under Affleck’s direction, breathing life into what started as nothing...

Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Evolve & ELITEWHEELS: Shifting Gears in European Cycling

Revving Up for the European Cycling Scene There's something about the open road and the whirr of wheels that gets blood pumping—maybe it's the competition, maybe it's the gear. Either way, this year's Italian Bike Festival is turning the Misano World Circuit into a battleground for cycling's elite, with evolve and ELITEWHEELS charging at the forefront. They're not just...

Virterion Surges Ahead in VPS Racing With Reliable Hosting

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Roborock Fuels Market Surge with 27.6% Revenue Boost

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...